文献速递浆细胞疾病

冒烟型多发性骨髓瘤的转变:现代早期骨髓瘤的重新定义

Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.
PubMed 文献 · Leukemia · 2026-05-05

本文综述了冒烟型多发性骨髓瘤(SMM)在分子生物学、现代影像学和免疫治疗进展推动下的认识转变。FDA近期批准达雷妥尤单抗用于高危SMM,标志着早期干预首次获得临床验证,挑战了传统「观察等待」范式。文章回顾了该领域进入新治疗时代的历程、局限及未来关键科学问题。

要点

  • FDA批准达雷妥尤单抗用于高危SMM,早期干预首次获临床验证。
  • 分子生物学、现代影像和免疫治疗进展重塑了对早期浆细胞疾病的认识。
  • 诊断边界、风险分层和传统「观察等待」范式正面临挑战。

核心结论

  • FDA批准达雷妥尤单抗用于高危SMM是历史性转折点,早期干预不仅可行且获临床验证。
  • 新兴技术可能将部分当前SMM患者重新定义为早期骨髓瘤,另一些则可能归为良性单克隆丙种球蛋白病。

研究设计与样本

  • 本文为综述,回顾SMM领域进入新治疗时代的历程、局限及未来关键科学问题。

主要发现

  • 过去十年分子生物学、现代影像学和免疫治疗的重大进展重塑了对早期浆细胞疾病的理解。
  • 达雷妥尤单抗获FDA批准用于高危SMM,首次使早期干预获得临床验证。

临床怎么用

  • 高危SMM可考虑早期干预而非传统观察等待,达雷妥尤单抗已获FDA批准。
  • 诊断边界与风险分层需结合分子生物学和现代影像学重新评估。

局限性

  • 文章指出当前框架存在局限性,并强调需明确塑造下一代SMM研究和诊疗的关键科学问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Smoldering multiple myeloma (SMM) has long been viewed as an intermediate precursor state, monitored until symptoms or organ dysfunction signaled the transition to active multiple myeloma (MM). Over the past decade, however, major advances in molecular biology, modern imaging, and immunotherapy have reshaped our understanding of early plasma cell disorders. The recent FDA approval of daratumumab for high-risk SMM marks a historic turning point. For the first time, early intervention is not only feasible but clinically validated. This evolving framework challenges long-standing assumptions regarding diagnostic boundaries, risk stratification, and the traditional "watch-and-wait" paradigm. It is logical to conjecture that emerging and future technologies will redefine portions of today's SMM population as early myeloma, while others may ultimately be reclassified as benign monoclonal gammopathies. An interesting question is whether there will be any SMM patients left? This article reviews how the field has arrived at this new therapeutic era, outlines its limitations, and highlights key scientific and clinical questions that will shape the next generation of SMM research and care.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Landgren O. Smoldering multiple myeloma in transition: redefining early myeloma in the modern era. Leukemia. 2026. PMID: 42086933. doi:10.1038/s41375-026-02979-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。